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Abstract
The production of ribosomes is ubiquitous and fundamental to life. As such, it is surprising
that defects in ribosome biogenesis underlie a growing number of symptomatically distinct
inherited disorders, collectively called ribosomopathies. We previously determined that the
nucleolar protein, NOL11, is essential for optimal pre-rRNA transcription and processing in
human tissue culture cells. However, the role of NOL11 in the development of a multicellular
organism remains unknown. Here, we reveal a critical function for NOL11 in vertebrate ribo-
some biogenesis and craniofacial development. Nol11 is strongly expressed in the develop-
ing cranial neural crest (CNC) of both amphibians and mammals, and knockdown of
Xenopus nol11 results in impaired pre-rRNA transcription and processing, increased apo-
ptosis, and abnormal development of the craniofacial cartilages. Inhibition of p53 rescues
this skeletal phenotype, but not the underlying ribosome biogenesis defect, demonstrating
an evolutionarily conserved control mechanism through which ribosome-impaired craniofa-
cial cells are removed. Excessive activation of this mechanism impairs craniofacial develop-
ment. Together, our findings reveal a novel requirement for Nol11 in craniofacial
development, present the first frog model of a ribosomopathy, and provide further insight
into the clinically important relationship between specific ribosome biogenesis proteins and
craniofacial cell survival.
Author Summary
All cells require ribosomes, the cellular factories that produce proteins. A host of factors
combine to produce the multiple complex units of a ribosome, many of which are still not
well understood. Surprisingly, despite the ubiquitous requirement for ribosomes, defects
in various ribosome biogenesis factors cause distinct and tissue specific phenotypes, collec-
tively known as ribosomopathies. We examined the role of one ribosome biogenesis factor,
Nol11, during embryonic development to determine if it too had a tissue specific
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phenotype. Here we show that expression of nol11 is strongly associated with the develop-
ing head in vertebrates and that insufficient Nol11 results in striking malformations of the
craniofacial skeleton. We further show that reduced Nol11 impairs critical early steps in ri-
bosome production, which triggers apoptosis within cell populations that contribute to the
head. Increased cell death is at least partially the cause of the Nol11 craniofacial defect; re-
ducing cell death rescues some of the craniofacial phenotype but not the ribosome biogen-
esis defect. In summary, we demonstrate for the first time that Nol11 is required for
normal development of the vertebrate head and provide novel insight into the intriguing
tissue proclivity of ribosomopathies.
Introduction
The synthesis of ribosomes, the protein-manufacturing entities in cells, is fundamental to all of
life. Therefore, it is surprising that defects in ribosome synthesis are compatible with the devel-
opment of a multicellular organism, albeit with substantial morbidity. Several diseases of ribo-
some biogenesis, so-called ribosomopathies, have been described with a strikingly
heterogeneous collection of symptomatologies [1–16]. The remarkable diversity of affected tis-
sues across the ribosomopathies raises the question of how different cell types can be selectively
affected by defects in the ubiquitous process of making ribosomes.
An emerging class of ribosomopathies includes craniofacial anomalies. Craniofacial malfor-
mations are associated with over 700 human congenital syndromes, and the molecular causes
of many of these diseases remain unknown [17]. Often the structures affected in craniofacial
syndromes are derivatives of the cranial neural crest (CNC), a vertebrate specific, multipotent
cell population that gives rise to a vast array of craniofacial tissues, including the majority of
the craniofacial skeleton [6,17–24]. Correct development of the CNC is a multistep process
that includes specification at the border of the embryonic neural and non-neural ectoderm, de-
lamination, migration to the facial primordia, proliferation and differentiation into normal cra-
niofacial structure and morphology. This elaborate process requires extensive cellular
modifications, and is carefully regulated at the molecular level [25–34]. Due to the clinical im-
portance of the CNC, and their potential for regenerative medicine based treatment strategies,
a detailed understanding of the control mechanisms underlying CNC development is a prima-
ry goal of craniofacial research.
Investigations into the surprising relationship between craniofacial disease and defects in ri-
bosome biogenesis are beginning to emerge. Defects in CNC derived craniofacial structures are
associated with the ribosomopathy known as Treacher-Collins Syndrome [6,15,16,21]. In Trea-
cher-Collins syndrome patients, mutations in the TCOF, POLR1C or POLR1D genes result in
impaired rDNA transcription and activation of the p53 mediated stress response in CNC cells
[5,6,16]. Heterozygote mouse models of Treacher-Collins syndrome in certain genetic back-
grounds recapitulate these craniofacial defects, which are dependent on p53 activation [6,21].
These results suggest that mechanisms regulating CNC survival may be particularly sensitive to
defects in ribosome production.
Ribosome biogenesis begins with the assembly of the nucleolus around ribosomal DNA
(rDNA) repeats and with the transcription of the polycistronic pre-ribosomal RNA (rRNA) pre-
cursor that contains the sequences for the 18S, 5.8S and 28S rRNAs by RNA polymerase I
(RNAPI). Over 200 ribosome biogenesis factors then process these rRNAs through a complex se-
ries of cleavages and modifications to assemble into the mature small (40S) and large (60S) sub-
units of the ribosome by incorporating 80 ribosomal proteins and the 5S rRNA [35–38].
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Maturation of the 18S rRNA is mediated by a large ribonucleoprotein called the small subunit
(SSU) processome [39–41]. Previous work in yeast has revealed that members of the t-Utp/UtpA
sub-complex of the SSU (Utp4, Utp5, Utp8, Utp9, Utp10, Utp15 and Utp17) are required for
both optimal transcription and processing of the pre-rRNA [42]. Likewise, the orthologs of most
of these proteins are also required for pre-rRNA processing and transcription in human cells. The
one exception is human Utp4, which is required for pre-rRNA processing but not for RNAPI
transcription [40]. Mutation of Wdr43, the zebrafish ortholog of yeast Utp5, results in p53 medi-
ated craniofacial malformations [42,43]. Interestingly, while the majority of t-UTP/UTPA sub-
complex proteins are conserved from yeast to humans, Utp8 and Utp9 constitute notable excep-
tions, suggesting that these t-Utp proteins may have evolved specific functions in vertebrates [40].
We recently discovered the human analog of yeast Utp8 to be NOL11, a metazoan-specific
nucleolar protein [44,45]. NOL11 was discovered by its interaction with the C-terminal region
of the known t-UTP/UTPA subcomplex member, hUTP4/Cirhin, the protein mutated in North
American Indian childhood cirrhosis (NAIC) [4,44]. NOL11 is localized to the nucleolus, the
site of ribosome biogenesis, where it associates with other proteins in the SSU processome to fa-
cilitate maturation of the small ribosomal subunit (40S). The NAIC mutation in hUTP4/Cirhin
reduces interaction with NOL11, implicating NOL11 in the pathogenesis of NAIC. NOL11 is
required to maintain nucleolar number and for pre-rRNA transcription and processing in
human tissue culture cells but its requirement in embryogenesis remains unknown [44].
Here, we used the frog Xenopus tropicalis to investigate its role in vertebrate development.
We report that nol11mRNA expression is strongly associated with the developing CNC in
both amphibians and mice. We further demonstrate that nol11 is required for optimal pre-
rRNA transcription and pre-rRNA processing in Xenopus, and that nol11 knockdown results
in activation of the nucleolar stress response, p53 stabilization, and a dramatic craniofacial phe-
notype. Importantly, the craniofacial defect can be partially rescued by p53 depletion, while the
underlying transcriptional defect cannot, demonstrating that the pathology is due to the cellu-
lar response to impaired ribosome biogenesis. Together, our findings reveal a novel require-
ment for Nol11 in craniofacial development and provide further insight into the evolutionarily
conserved relationship between specific ribosome biogenesis factors and the control mecha-
nisms that regulate CNC survival and development.
Results
Tissue specific expression of Nol11 during vertebrate development
As a first step in our analysis, we examined nol11mRNA expression during vertebrate embry-
onic development. Intriguingly, despite the ubiquitous need for ribosomes, in situ hybridiza-
tion of labelled anti-sense probes revealed robust, tissue specific expression of nol11mRNA in
both the frog and mouse. In Xenopus, transcripts are detected throughout the forming neural
tube, and signal is particularly strong in anterior regions, from which the CNC form, at stages
14–16 (Fig. 1). This association of nol11 expression and CNC development is maintained at
later stages of development (stages 22–36), where signal marks the CNC streams as they mi-
grate into the facial primordia and differentiate. During these stages, expression in the neural
tube becomes more restricted and is detected in regions of the hindbrain, isthmus and tail. Ad-
ditional stage specific expression is lightly detected in the optic and otic placodes, the ventral
blood islands, and diffusely in the presumptive splenic mesenchyme (Fig. 1).
Nol11 RNA is similarly expressed in the mouse CNC. At stage E8.5, murine Nol11 tran-
scripts are detected strongly in the anterior and posterior neural folds and presumptive CNC
regions. At stages E9.5 and E10.5 expression is largely restricted to CNC regions, including the
frontonasal prominence (FNP), the mandibular and maxillary portions of the first branchial
Nol11 Is Required for Craniofacial Development
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arch (mdBA1 and mxBA1) and the more posterior BA. Interestingly, in both mice and frogs,
Nol11 expression appears enriched in distal regions of the branchial arches at later stages of de-
velopment (Fig. 1). Murine expression was also observed in the optic placode, the trigeminal
region and otic placode, closely mirroring the Xenopus expression pattern, as well as in regions
of the developing gut and liver (Fig. 1, S1A Fig). Together, amphibian and murine expression
suggests an evolutionary conserved relationship between the ribosome biogenesis gene nol11
and development of the CNC.
Fig 1. Expression of nol11 during vertebrate development. A) Wild type nol11 expression pattern during
Xenopus tropicalis development. Note the strong expression in developing neural folds (NF) and the
presumptive CNC at stages 16 and 22 (lateral [left] and dorsal [right] views presented). Expression is strongly
associated with the migrating and differentiating CNC at subsequent stages, and is also detected in the
region of the ventral blood islands (BI) and isthmus (Is) at stage 28. BA, branchial arch; Ht, heart; Lv, liver
region; Op, optic placode. B) and C) Anterior transverse dissections showing expression of nol11 in neural
folds and premigratory CNC of stage 14 and 16 embryos respectively. Plane of dissection is represented by
the red dotted line marked c in A. D) Horizontal dissection (shown as dotted red line marked d in A) of nol11
expression in the branchial arches of stage 28 Xenopus embryos. E) nol11 expression in E8.5, E9.5 and
E10.5 wild type mouse embryos. At E8.5 expression is strongly detected in the neural folds. Transcripts are
associated with CNC positive regions at both E9.5 and E10.5. BA2, 2nd branchial arch; FNP, frontonasal
prominence; Ht, heart; mdBA1, mandibular BA1; mxBA1, maxillary BA1; Op, optic placode; Ot, otic placode;
T, trigeminal region.
doi:10.1371/journal.pgen.1005018.g001
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Xenopus nol11 is required for normal CNC development and formation
of the craniofacial skeleton
To test if nol11 is required for CNC development, we employed morpholino oligo (MO) me-
diated knockdown in Xenopus tropicalis. In Xenopus, MOs can be injected at the one cell
stage targeting the entire embryo or at the two-cell stage where embryos targeted to either
just the right or left side can be selected. To test the efficacy of our knockdown, we examined
Nol11 protein levels in uninjected controls (UC) and nol11morphants by western blot, and
confirmed a dose dependent impact on Nol11 protein levels during development (S2 Fig).
Knockdown of nol11 resulted in microcephaly and pronounced defects in CNC derived
craniofacial cartilages in 86% (n = 389) of treated embryos, while control MO (CMO) in-
jected embryos were unaltered (Fig. 2A and 2C). Cartilaginous defects included significantly
reduced size and dysmorphology of the Meckel’s, quadrate, ceratohyal and branchial carti-
lages at stage 45, (Fig. 2A and 2B). The severity of these defects varied from a 27% to 55% re-
duction in cartilage size, with an average reduction of 42% (Fig. 2B). These cartilages are
derivatives of distinct branchial arches (BAs) and neural crest migratory streams, and their
loss demonstrates a central role for nol11 in CNC development, independent of axial level of
origin. nol11morphants did not survive beyond stage 45–47, probably due to a non-
functional jaw apparatus and a reduced ability to feed. To test the specificity of the nol11
MO, we injected human NOL11mRNA into one cell of two cell stage nol11morphants and
compared the two sides. NOL11mRNA rescued both cartilage size and morphology in 74%
of embryos (Fig. 2C).
To probe the ontogeny of these cartilaginous defects, we next examined development of the
CNC in nol11morphants. We found that initial specification of dorsal territories and neural
tissue proceeds normally in nol11morphants, as assayed by expression of the pan-neural mark-
er sox3, the exclusion of cytokeratin expression from neural tissue, and expression of pax2 and
myod in the developing neural tube and somites respectively at stage 14/15 [46–48] (Fig. 3, S3
Fig). With the exception of a slight delay, expression of the CNC master genes twist, slug, ap2
and sox9 [49–51] also appeared normal relative to controls at stages 14 and 24, suggesting that
induction, delamination and migration of the CNC occurs in a largely normal fashion follow-
ing nol11 knockdown (Fig. 3, S3A Fig). However, by stage 28, defects in CNCmarkers are read-
ily apparent within the developing BAs. These include striking reductions in sox9 expression
(a CNC gene required for cartilage differentiation), as well as CNC patterning genes including
gsc, dlx5, twist, dlx2 and xnot (Fig. 3, S3 Fig). Importantly, the branchial arches were also ob-
served to be smaller on the treated side of the embryo, suggesting a reduced number of CNC
cells (Fig. 3, S3 Fig). While the medio-lateral size of the neural tube appeared slightly reduced
in morphants at stage 28, patterning of the neural tube and brain appeared grossly intact, as as-
sayed by expression of pax2, hoxb3, and sox3 (S3B Fig).
To test if patterning defects were selective for the CNC, we assayed various markers for dif-
ferent organs testing cardiac, gut and kidney development. Both cardiac looping and pitx2 ex-
pression were normal in morphants (S1B, D Fig), demonstrating that the strong nol11
expression observed in the embryonic left-right organizer is not required for normal organ
situs [52]. Gut morphology was abnormal in morphants at stage 45. We also examined expres-
sion of nkx2.5, pax2, sglt1, smp30 and hex in stage 28–36 nol11morphants but found no
marked changes (S1C, E, F Fig). Interestingly while expression of the cardiac and splenic pat-
terning gene nkx2.5 [53,54] appeared normally positioned in morphants, its splenic expres-
sion appeared moderately reduced, suggesting a possible role for nol11 in spleen development
(S1C Fig). In future studies, it will be interesting to examine late stage development of
additional organs.
Nol11 Is Required for Craniofacial Development
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The Nol11 craniofacial defect is associated with increased apoptosis
As mutations in ribosomal biogenesis factors have previously been associated with altered cell
survival and since the reduced size of the BAs in nol11morphants suggests reduced cell num-
bers, we next examined rates of apoptosis and proliferation in the facial primordia of nol11 de-
pleted embryos. At early stages of development, no significant change was observed in
apoptosis rates as assayed by TUNEL staining and p53 protein levels (Fig. 4A). However by
stages 18 through 28, as the CNC migrate into and become patterned within the facial primor-
dia, we observed a dramatic 3–4 fold increase in the number of TUNEL stained cells (Fig. 4A,
S4 Fig). This increase correlates well with the observed onset of the cartilage phenotype. Exami-
nation of TUNEL staining in paraffin sections revealed the increased apoptosis to be largely
confined to ectomesenchymal cells located with the facial primordia, possibly CNC (Fig. 4A).
Western blot analysis of p53 protein levels in morphants revealed approximately normal pro-
tein levels at early time points (st12–14) but a progressive increase over subsequent stages, cul-
minating in an approximately 4-fold increase between stages 18–28. These findings mirror the
Fig 2. The nol11 craniofacial phenotype. A) Gross morphology and cartilage staining of UC, nol11whole embryo, nol11 one-sided knockdowns and CMO
one-sided knockdown embryos. Note the reduced cartilage size and abnormal morphology in nol11morphants (red arrowheads) while CMO injected
embryos are unaffected. B) Craniofacial cartilage size is significantly reduced in nol11 but not CMOmorphants. C) Co-injection of human NOL11 RNA can
rescue the cartilage phenotype in approximately 75% of treated embryos. Cartilage staining of an RNA rescued embryo; nol11MOwas injected at the one
cell stage and humanNOL11 RNA was injected into one cell at the two cell stage. Green arrowheads highlight rescued side.
doi:10.1371/journal.pgen.1005018.g002
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TUNEL results and confirm a stage dependent increase in apoptosis (Fig. 4A, Fig. 5D). Inter-
estingly, in contrast to observations in the zebrafish Wdr43 mutant, nol11 morphants did not
have a significant change in rates of proliferation (Fig. 4B).
In order to confirm that this increase in apoptosis contributes to the nol11 craniofacial phe-
notype, we next asked if knockdown of p53 could rescue the malformation. Interestingly,
Fig 3. Knockdown of nol11 disrupts cranial neural crest development. At stages 14 and 24 neural and
CNC development appears normal in one side treated embryos, as assayed by expression of key marker genes
including sox3, cytokeratin, twist and slug. By stage 28 however, reductions are apparent in the expression of
numerous CNC genes. The branchial arches are also smaller on theMO treated side at stage 28. Graph
displays number of embryos exhibiting abnormal gene expression in control and nol11morphant embryos.
doi:10.1371/journal.pgen.1005018.g003
Nol11 Is Required for Craniofacial Development
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injection of p53 MO alone into wild type Xenopus embryos produces a dose dependent cranio-
facial defect, most plausibly due to disruption of normal patterns of cell death during develop-
ment or, as previously reported, apoptosis independent effects [55,56]. However, we found that
by titrating the p53 knockdown we could ameloriate some of the nol11 cartilage phenotype, in-
cluding improved cartilage size and morphology (Fig. 4C). The efficacy of the p53 MO in re-
ducing p53 protein levels was demonstrated by western blot (Fig. 4D). We also found that
injection of p53 MO dramatically reduced rates of cell death within the branchial arches of
stage 28 nol11morphants, while CMO had no effect (S4 Fig). Together these findings suggest
Fig 4. Increased apoptosis underlies the nol11 cartilage defects. A) nol11 knockdown results in a progressive increase in apoptosis. At stage 14 no
significant difference was observed in rates of TUNEL staining between knockdown and control halves of the embryo. At stages 18 and 28 increased
apoptosis was evident on the treated side of whole mount and sectioned paraffin embedded embryos. Note that this increased apoptosis occurs primarily
within the craniofacial ectomesenchyme. The graph represents the relative quantification of apoptosis rates at stages 14, 18 and 28. This stage specific
increase in apoptosis was confirmed by a similar increase in p53 protein levels in 1 cell injected embryos as assayed by western blot (lower right panel).
Dotted red lines mark the embryonic midline. B) No significant change in proliferation rates was noted following nol11 knockdown. C) Inhibition of apoptosis
by p53 MO results in a partial rescue of cartilage size and morphology. Each pair of columns in the graph compares cartilage size measured in bilateral
halves of embryos. The blue pair reveals no significant difference in cartilage measurements in the left vs right side of the UC embryonic head. In the second
pair (red), cartilage size is seen to be comparable on either side of the nol11morphant head. The final pair illustrates that cartilage size is significantly
improved on the side of nol11morphants rescued with p53 MO (green) relative to the side that received nol11MO only (red). D) Western blot demonstrating
that the p53 MO efficiently reduces p53 protein levels in nol11morphants.
doi:10.1371/journal.pgen.1005018.g004
Nol11 Is Required for Craniofacial Development
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Fig 5. Nol11 depletion impairs rDNA transcription and pre-rRNA processing in X. tropicalis. A) Scheme of pre-rRNA processing pathways in X
tropicalis. The pre-rRNA is transcribed by RNAPI as a 40S polycistronic precursor. Several cleavages are required to separate the mature rRNAs. The
Nol11 Is Required for Craniofacial Development
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that the nol11 craniofacial phenotype is at least in part caused by an increase in p53 mediated
cell death within the cells that populate the facial primordia.
Nol11 is required for ribosome biogenesis in a developing embryo
Increased tissue specific apoptosis is associated with disruption of several ribosome biogenesis
factors, including Tcof1, the protein that is mutated in Treacher-Collins syndrome
[1,6,21,43,57]. Under conditions of defective ribosome biogenesis, this apoptotic response is
triggered by the ‘nucleolar stress response’, the binding of excess ribosomal proteins, such as
RPL5 and RPL11, to Mdm2, which in turn prevents Mdm2 mediated p53 degradation [58].
With this in mind, we sought to investigate whether pre-rRNA processing and transcription,
and thus ribosome biogenesis are disrupted in nol11morphants.
To develop probes for northern blots to examine ribosome biogenesis in X. tropicalis, we
first identified the X. tropicalis 5’ external transcribed spacer (ETS) in the pre-rRNA using a
BLAST search. Aligning X. laevis and X. borealis pre-rRNA sequences, we identified two X. tro-
picalis Xentr7.1 scaffolds (xenbase.org). Scaffold sequence 169 contained sequences similar to
X. laevis 5’ETS, 18S rRNA, internal transcribed spacer 1 (ITS1), and the 5’ portion of the 5.8S
rRNA while scaffold 2385 only contained sequence similar to the 5’ portion of the 5’ETS (S5
Fig). Using these alignments we designed oligonucleotides that were reverse complements of
sequences in the 5’ETS and ITS1 of X. tropicalis since NOL11 is required for biogenesis of the
mature 18S rRNA in human cells [44]
Using these oligonucleotide probes (probes a,c indicated in Fig. 5A), we investigated the ef-
fect of nol11 knockdown on ribosome biogenesis in X. tropicalis embryos by northern blot
analysis (Fig. 5B and 5C). Hybridization to the 7SL SRP RNA was carried out as a loading con-
trol, as done previously [59]. Northern blots were repeated 3 times with the indicated embryos.
The results were quantified and studied by Ratio Analysis of Multiple Precursors (RAMP; S5
Fig; [60]). With either probe at either stage 12 or stage 28, no significant difference was ob-
served either by eye (Fig. 5B and 5C) or in the RAMP profile between uninjected controls (UC)
and control morpholino injected embryos (CMO) (S6 Fig), indicating that injection per se does
not result in defects in ribosome biogenesis as detected by northern blots.
We do, however, observe defects in transcription and pre-rRNA processing in nol11mor-
phants, indicating that depletion of Nol11 results in defective ribosome biogenesis. In northern
blot analysis with probe a, steady state levels of both the 40S pre-rRNA primary transcript and
its 20S pre-rRNA processed product were reduced in stage 28 nol11morphants (Fig. 5B, lanes
4–6; S6B Fig). In contrast, no significant difference was detected between nol11morphants and
the controls at stage 12 (Fig. 5B, lane 1–3; S6A Fig). The marked decrease in steady state levels
of both pre-rRNA transcripts in nol11MO-treated embryos at stage 28 is consistent with a de-
fect in pre-rRNA transcription following Nol11 knockdown.
Likewise, northern blot analysis with probe c revealed defects in transcription and pre-
rRNA processing in nol11MO-treated embryos. When the levels of the indicated pre-rRNAs
locations of oligonucleotide probes used for northern blots are indicated by lettered lines (a, c) and the cleavage sites indicated. This scheme was adapted
from [71–75]. B) Morpholino (MO) depletion of Nol11 impairs pre-rRNA transcription at stage 28. The northern blot was hybridized with probe a (Fig. 5A) and
with a probe to the 7SL RNA as a loading control (lower panel). Bands were quantified and analysed by RAMP ([60]; S6A,B Fig) C) Morpholino (MO)
depletion of Nol11 impairs pre-rRNA transcription and processing. The northern blot was hybridized with probe c (Fig. 5A) and with a probe to the 7SL RNA
as a loading control (lower panel). Bands were quantified and analysed by RAMP ([60]; S6C,D, E, F Fig). D) Depletion of Nol11 leads to increased p53 levels.
The expression of p53 from control and nol11 depleted embryos was analysed by western blot with anti-p53 antibodies. GAPDH levels were used as a
loading control. Values for p53 expression normalized to GAPDH are represented in the bar graph. E) MO-resistant human NOL11 (hNOL11) mRNA but not
p53 depletion rescues pre-rRNA levels. Embryos injected as shown by + and—in the figure at stages 22 and 28. The pre-rRNAs were visualized with probe a
on a northern blot; hybridization to the 7SL RNA was used as a loading control.
doi:10.1371/journal.pgen.1005018.g005
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were compared to the 7SL RNA loading control in nol11morphants, a significant decrease in
the 40S, 36S and 20S pre-rRNAs was detected at stage 28 (Fig. 5C, lanes 4–6; S6D Fig). This is
consistent with a defect in pre-rRNA transcription. At the same time, the 19S pre-rRNA
(Fig. 5A) accumulated in nol11MO-treated embryos at stage 28 (Fig. 5C, lanes 4–6; S6D Fig),
consistent with a defect in pre-RNA processing. No significant difference was detected between
nol11morphants and the controls at stage 12 when the pre-rRNA levels were compared to the
7SL RNA loading control (Fig. 5C, lane 1–3; S6C Fig). However, when the levels of the indicat-
ed pre-rRNAs were compared to each other in nol11morphants, accumulation of the 19S pre-
rRNA could be observed as early as stage 12 (Fig. 5C, lane 3; S6E Fig) and was very pronounced
by stage 28 (Fig. 5C, lane 6; S6F Fig). Thus, depletion of Nol11 by injection of MO in develop-
ing X. tropicalis embryos results in defective pre-rRNA transcription and processing.
As discussed above, defects in ribosome biogenesis can lead to p53 stabilization and subse-
quent apoptosis due to a cellular phenomenon known as nucleolar stress [61–63]. In order to
further examine the relationship between the pre-RNA transcription defect and increased p53
expression, we compared changes in both over the relevant embryonic time course. As de-
scribed above, MO-depletion of nol11 caused an increasingly severe disruption of pre-RNA
transcription over these developmental stages (Fig. 5B and 5C, lane 6; S6B,D Fig). We found
that this correlated precisely with the progressive increase in p53 levels by western blot
(Fig. 5D). Together, these findings indicate that nol11 depletion results in reduced pre-RNA
transcription, impaired ribosome biogenesis and increased levels of p53, a hallmark of
nucleolar stress.
To confirm that these defects are specific to nol11 depletion, we compared nol11morphants
with morphants rescued with NOL11 mRNA. Co-injection of the human NOL11 mRNA res-
cued the steady state levels of the pre-rRNAs in morphants (Fig. 5E, lanes 3 and 7) indicating
restoration of pre-rRNA transcription and therefore ribosome biogenesis. In addition, co-de-
pletion of p53 and Nol11 did not rescue the pre-rRNA transcription defect although we did
find a partial rescue of the craniofacial phenotype (Fig. 5E, lanes 4, 8 and Fig. 4C, above).
Discussion
Ribosome biogenesis is a vital and energy intensive process, requiring the interaction of hun-
dreds of proteins and the majority of a cell’s transcriptional output. As such, it is not surprising
that it is carefully monitored, or that a control mechanism such as the nucleolar stress response
exists to remove compromised cells. Indeed, impaired ribosome production is frequently asso-
ciated with apoptosis. For example, Treacher-Collins syndrome is molecularly characterized by
impaired ribosome biogenesis, activation of the nucleolar stress response and increased p53
levels in CNC cells [6,21]. A similar increase in apoptosis has been reported to underlie the zeb-
rafish Wdr43 (Utp5) craniofacial phenotype [43]. Importantly, the observation that inhibition
of apoptosis can rescue the cartilage phenotype but not the underlying transcriptional and pro-
cessing defect in both Xenopus nol11morphants and some mouse Treacher-Collins Syndrome
models demonstrates that it is the evolutionary conserved nucleolar stress response, and not
the ribosomal defect per se, that produces the craniofacial malformation. As such, further in-
vestigation and modulation of this stress response may ultimately provide novel treatment op-
tions for apoptosis induced ribosomopathies. Together with previous studies, our data provide
further evidence that the CNC are particularly sensitive to insufficiency of certain ribosome
biogenesis proteins and reveal a common, evolutionarily conserved control mechanism
through which compromised multipotent CNC are eliminated in the embryo. This sensitivity
of CNC to ribosome biogenesis defects also suggests that mutations in nucleolar factors may
contribute to additional currently unexplained human congenital defects.
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The finding that defects in presumably globally required ribosome biogenesis factors can
produce tissue specific defects is an intriguing emerging facet of embryonic development. Sev-
eral human diseases are now known to result from mutations in ribosome production and
present with distinct phenotypes [1–4,6,8,9,11,14,16,44,64,65]. The mechanisms underlying
the tissue specificity of these ribosome biogenesis factors remain unknown but may include dif-
ferential ribosomal biogenesis factor requirements during the development of distinct tissues
or a heightened sensitivity to impaired protein production in particular cell populations. While
the CNC is a highly active embryonic cell population, the distinct phenotypes observed in
human ribosomopathies, many of which do not include craniofacial defects, would seem to
argue against the latter scenario. Furthermore, experimental support for the differential re-
quirements hypothesis is beginning to emerge from studies of both mice and zebrafish
[6,43,57,66]. Our findings that nol11 expression at the mRNA level is tightly linked to CNC
cells, where it is required for normal differentiation and development of craniofacial cartilages,
but not detected in, or associated with overt defects in the development of several other active
cell populations at similar stages, provides strong support for the possibility of differential ribo-
somal protein requirements during embryonic development. While beyond the scope of this
work, a future comparison of RNA translation and protein profiles between the CNC and non-
CNC cells of wild-type and knockdown embryos would be highly informative.
Importantly, the role of the NOL11 protein in ribosome biogenesis is conserved between
human cells and X. tropicalis embryos. In HeLa cells [44] and in developing frog embryos, de-
pletion of NOL11 results in defects in pre-rRNA transcription and pre-18S rRNA processing.
However, the precise pattern of the pre-rRNAs differs between the two species even in the
non-depleted state, with the pattern in X. tropicalis similar to that found in zebrafish (D. rerio)
[43,67]. Whether this is due to differences among vertebrate species or differences between tis-
sue culture cells and a developing organism we do not yet know. The development of oligonu-
cleotide probes to study these pre-rRNA pathways in X. tropicalis should thus facilitate the
mapping of steps in pre-rRNA processing in this developing frog.
In summary, we have demonstrated a novel role for nol11 in vertebrate ribosome biogenesis,
cell survival and craniofacial development. The emerging relationship between specific ribo-
some biogenesis factors and tissue specific developmental defects is an unexpected and intrigu-
ing feature of developmental biology, and one that may underlie numerous currently
unexplained congenital syndromes. Our findings provide insight into this relationship and
highlight the utility of Xenopus tropicalis as a model for further investigations of
human ribosomopathies.
Materials and Methods
Ethics statement
X. tropicalis were maintained and cared for in our aquatics facility, in accordance with Yale
University Institutional Animal Care and Use Committee protocols.
Embryos
Embryos were produced by in vitro fertilization and raised to appropriate stages in 1/9MR +
gentamycin. Fixed wild-type mouse embryos were obtained from C. Wilson and C. Bogue.
Antisense morpholino knockdown
Antisense morpholino oligonucleotides targeting the nol11 translational start site
(5’ GCTCCCCGAGAGCGGCCATCTTGTC 3’), or standard CMO from Genetools LLC,
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Philomath, OR) were injected at either the one cell stage (2ng MO) or into one cell at the two-
cell stage (1ng MO). A full-length cDNA clone of human NOL11 was purchased from Open
Biosystems and subcloned into the Gateway Entry vector pDONR221 (Invitrogen). The speci-
ficity of the MO was then tested by injecting 2ng of nol11MO at the one cell stage and subse-
quently injecting 50pg of human NOL11 RNA into one cell at the two cell stage in order to
rescue the phenotype on the RNA treated side. Rescue was scored by increased cartilage size
and morphology.
Whole-mount in situ hybridization
Xenopus nol11 template for probe was amplified from wild type cDNA using the following
primer combinations: forward: 5’- AGTTTGGTGAGGCGCTGTAT-3’; reverse: 5’-
GGCTCATCCAATCCACTACC-3’ and then TOPO TA cloned (Life Technologies) as per
manufacturer’s instructions. Digoxigenin-labeled antisense probes for ap-2, TGas030K20;
cytokeratin, IMAGE:6991625; dlx2, IMAGE:6980076; dlx5, TNeu071c08; gsc, TGas129E16;
hex, TGas075h17;myoD, TNeu017H11; nkx2.5, IMAGE:7517699; nol11, as described above;
pax2, TNeu062i10; pitx2, TNeu083k20; sglt, IMAGE:5308256; sox9, TNeu111f21; slug,
TNeu008A21; smp-30, IMAGE:6999181; twist, TNeu125e01 and xnot, TNeu017e01 were in
vitro transcribed with T7 High Yield RNA Synthesis Kit (E2040S) from New England Biolabs.
Embryos were collected at the desired stages, fixed in MEMFA for 1–2 hours at room temper-
ature and dehydrated into 100% ETOH. Whole mount in situ hybridization was performed as
described previously [68]. Embryos were stained with BM Purple and examined after equili-
bration in 100% glycerol.
Alcian Blue staining and measurements of cartilage
Stage 45 embryos were fixed in MEMFA for 20 mins at RT and then washed in acid alcohol
(1.2% HCL in 70% ETOH) before staining in 0.5% alcian blue solution in acid alcohol over
night at 4 degrees. Samples were then washed several times in acid alcohol and dehydrated into
H2O, before bleaching for 1–2 hrs in 1.2% hydrogen peroxide. Samples were then washed sev-
eral times in 2% KOH and left rocking overnight in 10% glycerol in 2% KOH. They were then
processed through 20%, 40%, 60% and 80% glycerol in 2% KOH. The facial cartilages were
then dissected out and imaged using a Canon EOS 5d digital camera mounted on a Zeiss dis-
covery V8 stereomicroscope. Bilateral cartilages were then outlined using ImageJ software
(NIH) and their relative sizes measured.
Western blotting
Pools of ten staged control and morphant embryos were collected and placed in 100ul of 1 x
RIPA buffer. Embryos were then crushed using a pestle and spun down twice to separate protein
from fat and debris. Western blots were then carried out following standard protocols, using an
anti-p53 (Thermo Scientific, MA1–12549 1:800 dilution) or an anti-NOL11 (SIGMA
HPA022010 1:1000 dilution) primary antibody and an anti-mouse or anti-rabbit HRP conjugat-
ed secondary (Jackson Immuno Research Laboratories, 715–035–150 or 211–032–171 1:15000
dilution). Anti-GAPDH (Ambion, AM4300 1:5000 dilution) was used as an internal control.
Quantifications of changes in protein level were calculated using ImageJ software from NIH.
TUNEL and proliferation assays
Whole mount TUNEL staining of developmentally staged wild-type and nol11 morphant em-
bryos was carried out as previously described [69]. Stage 28 embryos were also fixed in 4%
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paraformaldehyde, embedded in paraffin and cut into 10 μm sections. The TUNEL assay was
carried out using the In situ cell death detection kit, Fluorescein (Roche Applied Science,
11684795910) as per the manufactures instructions (using the trypsin pretreatment option de-
scribed). Cell proliferation assays were carried out using an anti-phospho-Histone H3 antibody
(Millipore, 06–570) and an Alexa Fluor 488 Chicken Anti-Rabbit (Life Technologies, A21441).
Apoptosis rescue
In order to determine if the nol11 phenotype is due to increased apoptosis, we injected 2ng of
nol11MO at the one cell stage. A subset of these embryos were then injected with 1ng of p53
MO into one cell at the two cell stage to rescue the phenotype on the p53 MO treated side. Res-
cue was scored by measuring and comparing the area of cartilage present on the nol11MO
only vs the nol11 + p53MO treated sides of the midline using ImageJ software from NIH. Simi-
lar comparisons were made between the left and right sides of uninjected and nol11MO only
embryos as controls.
Statistical analyses
Each experiment was performed a minimum of three times. Statistical significance of the fre-
quency of CNC patterning gene disruptions was tested with a Chi-squared test. The signifi-
cance of TUNEL rates, changes in cartilage size and rescue experiments was evaluated using
paired or unpaired, two-tailed student’s t- tests as appropriate.
Northern blotting
X. tropicalis embryos were injected with MOs and mRNA as described. RNA was harvested
from embryos by dissolving 10–15 embryos in TRIzol (Invitrogen) and total RNA was ex-
tracted per the manufacturer’s instructions. Northern blot analyses were performed as de-
scribed previously [70]. Two or four μg of total RNA per sample were separated by gel
electrophoresis on a 1% agarose/1.25% formaldehyde gel and then transferred to a nylon mem-
brane (Hybond-XL, GE Healthcare). RNA species were detected by hybridization with radiola-
belled oligonucleotide probes or by methylene blue staining. Oligonucleotide probes are as
follows: Probe a, 5’-CAC TAA GGG TCA ACC TCT CCT T-3’; Probe c, 5’-CAG GTA CCC
GGG TCG GCC TGC GGC G-3'; 7SL: 5’- CAT ATT GAT ACC GAA CTT AGT GC-3’.
Northern blots were quantitated using a phosphorimager (Bio-Rad Personal Molecular Im-
ager) and the levels of all RNAs were normalized to the uninjected control. Ratio Analysis of
Multiple Precursors (RAMP) was performed as in [60]. Statistical analysis was performed
using a 2-way ANOVA with Tukey’s multiple comparisons test for post hoc analysis of signifi-
cance in GraphPad Prism.
Supporting Information
S1 Fig. nol11 in vertebrate development. A) Whole mount in situ hybridization of digoxi-
genin labelled Nol11 probe in E9.5 and E10.5 mouse embryos (E10.5 sample shown has been
hemisected). BA, branchial arch; FNP, frontonasal prominence; Ht, heart; mdBA1, mandibular
BA1; mxBA1, maxillary BA1; Op, optic placode; Ot, otic placode. B) Gross morphology of
stage 45 nol11morphants. Gut morphology is abnormal in morphants, while organ situs ap-
pears largely normal relative to wild type controls. Heart (red), gall bladder (green) and gut
(yellow) are pseudocoloured in lower right panels. C) Left sided expression nkx2.5 is reduced
or absent in the splenic anlage of a subset of nol11morphants (compare red arrowheads). D)
Example of the normal sided pitx2 expression present in nol11 knocked down embryos. E)
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Kidney development appears largely intact in nol11MO treated side compared to control side.
F) Quantification of number of embryos displaying the described phenotypes.
(TIF)
S2 Fig. Efficacy of the nol11MO. A)Western blot demonstrating that injection of nol11MO
at the one cell stage reduces Nol11 protein levels at stage 28 in a dose dependent manner. C,
control, 2, 2ng nol11 MO, 3, 3ng nol11 MO. B) Injection of 2ng of nol11MO at the one cell
stage results in a 30% reduction of protein level at stage 15 and a 44% reduction at stage 23.
(TIF)
S3 Fig. Patterning and apoptosis in nol11morphants. A) Somite, CNC and neural develop-
ment appear intact in nol11morphants at stage 14 as assayed bymyoD, ap2 and pax2 expres-
sion. Expression of xnot appears reduced at stage 28. B) Reduced dlx5 expression and BA
hypoplasia on treated side of a stage 28 embryo. Neural patterning is normal at this stage as as-
sayed by expression of pax2, hoxb3 and sox3. C) Whole mount TUNEL staining of treated and
untreated sides of a stage 28 embryo. Note the increased staining in the craniofacial regions of
the morphant side.
(TIF)
S4 Fig. Rates of cell death in the branchial arches. A) Graph of the number of Tunel positive
cells per 100 cells present in sections of the branchial arch region of stage 28 UC, CMO, Nol11
MO, Nol11 MO + p53 MO, and p53 MO only injected embryos ( = P< 0.05). B) Whole
mount stage 28 embryo with plane of section represented by the red dotted line. Representative
Tunel stained (green) sections from each control and morphants.
(TIF)
S5 Fig. The X. tropicalis 5’ external transcribed spacer. The 5’ETS sequences for X. laevis
(GeneBank ID: X02995.1; nucleotides 318–1029) and X. borealis (GeneBank ID: X00184.1; nu-
cleotides 545–1156) were aligned to X. tropicalis scaffolds 169 and 2385 from the
Xentr7.1 database.
(TIF)
S6 Fig. Statistical analysis of pre-rRNA levels by Ratio Analysis of Multiple Precursors
(RAMP) [60]. RNAs were quantitated from northern blots using a phosphorimager (Bio-Rad
Personal Molecular Imager). All ratios are representative of three biological replicates (n = 3).
The levels of all RNAs were normalized to the uninjected control (UC). All statistical analyses
for significance for Nol11-depleted embryos (NOL11) were performed compared to the control
morpholino injected embryos (CMO). A. Pre-rRNA levels in Nol11-depleted embryos are not
significantly affected at stage 12 compared to CMO as shown by a probe in the 5’ETS (probe
a). B. At stage 28, the levels of 40S and 20S pre-rRNAs, are significantly decreased relative to
the loading control 7SL RNA for Nol11-depleted embryos compared to CMO as shown by
probe a. This is consistent with decreased pre-rRNA transcription. C. Pre-rRNA levels relative
to the 7SL RNA for Nol11-depleted embryos are not significantly affected compared to CMO
at stage 12 as shown by a probe in the ITS1 (probe c). D. At stage 28 for Nol11-depleted embry-
os, the 40S, 36S, and 20S pre-rRNAs are all significantly decreased relative to the 7SL RNA
compared to CMO as shown by probe c. This is consistent with decreased pre-rRNA transcrip-
tion. However, the levels of 19S are significantly increased relative to the 7SL RNA compared
to CMO as this precursor accumulates in Nol11-depleted embryos. This is indicative of a pre-
rRNA processing defect. E. and F. For both stage 12 and 28 Nol11-depleted embryos, the ratios
of 19S/40S, 19S/36S, and 19S/20S are significantly increased compared to CMO indicating ac-
cumulation of the 19S pre-rRNA relative to the other three pre-rRNAs that hybridize with
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probe c. This is indicative of a pre-rRNA processing defect. [ns = p>0.05 (not significant),  =
p0.05,  = p0.01,  = p0.001,  = p0.0001]
(TIF)
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